In December 2023, C4 Therapeutics and Merck (known as MSD outside of the U.S. and Canada) entered into a license and research collaboration to discover and develop degrader-antibody conjugates (DACs). Under the terms of the agreement, C4T and Merck will collaborate to develop DACs directed to an initial undisclosed oncology target exclusive to the collaboration. Merck has the option to extend the collaboration to include three additional targets that would be exclusive to the collaboration. C4T will be responsible for using its proprietary TORPEDO® platform to develop degrader payloads in the discovery phase. Merck will be responsible for antibody conjugation to create DACs in the discovery phase and for advancing these DAC candidates through preclinical and clinical development as well as commercialization.
Partner with Us
Interested in partnering with us to leverage our MonoDAC℠ or BiDAC℠ research and development capabilities to bring degrader-based medicines to patients?Email Us To Collaborate